



PATENT
Attorney Docket: 31780.0037

#11/B
MB
04/29/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Application of: SELLERS *et al.*

Application No.: 09/584,669

Group Art Unit: 1651

APR 25 2002

Filed: June 1, 2000

Examiner: M.V. Meller

TECH CENTER 1600/2900

For: THERAPEUTIC AND DIAGNOSTIC METHODS DEPENDENT ON CYP2A
ENZYMES

AMENDMENT UNDER 37 CFR § 1.111

Commissioner for Patents
Washington, D.C. 20231

In response to the Office Action mailed November 23, 2001, please enter the following amendments and consider the following remarks intended to put this application into form for allowance. Applicants submit herewith: (a) Exhibit A, a marked up version of the claims showing the amendments made herein; (b) Exhibit B, a partial list of claims that will be pending upon entry of the amendment; (c) a Petition for Extension of Time for two (2) months, up to and including April 23, 2002, with a check for the required fee concurrently with the present amendment; and (d) a substitute declaration and power of attorney.

IN THE CLAIMS:

A marked up version of the claims showing the amendments is attached hereto as Exhibit A. Matter that has been deleted from claims 22-24 is indicated by brackets and matter that has been added to the claims is indicated by underlining.

22. A method for enhancing the effectiveness of nicotine replacement therapy comprising contemporaneously administering to an individual in need (a) nicotine and (b) one or more substances selected from the group consisting of (i) substances which inhibit CYP2A activity; (ii) substances which inhibit transcription, and/or translation of the gene encoding CYP2A activity; and (iii) substances which delete all or a portion of the gene encoding CYP2A.

Pilocarpine

Sub
C1